4 PORT: Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. (clinicaltrials.gov) - Oct 8, 2026 - P4 | N=20 | Not yet recruiting | Sponsor: Southeast Retina Center, Georgia
New P4 trial • Diabetes • Diabetic Retinopathy • Hematological Disorders • Metabolic Disorders • Retinal Disorders
|